Study of XIAP Antisense for Advanced Cancers

NCT00385775 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
30
Enrollment
INDUSTRY
Sponsor class

Stopped Dosing cohort (650mg) exceeded current 350mg dosing in other trials.

Conditions

Interventions

Sponsor

Aegera Therapeutics